Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial

摘要: Lorcaserin is a serotonin 5-hydroxytryptamine 2c receptor agonist effective in treating obesity. Studies rodents have shown that lorcaserin acts the brain to exert its weight-reducing effects, but this has not yet been studied humans. We performed randomized, placebo-controlled, double-blind trial with 48 obese participants and used functional MRI study effects of on brain. Subjects taking had decreased activations attention-related parietal visual cortices response highly palatable food cues at 1 week fasting state cortex any 4 weeks fed state. Decreases emotion- salience-related limbic activity, including insula amygdala, were attenuated weeks. caloric intake, weight, BMI correlated parietal, baseline. These data suggest exerts by decreasing (parietal cortices) emotional activity (insula, amygdala). Results indicating baseline activation amygdala relates increased efficacy would be particular benefit eaters.